Response Element News Today

/PRNewswire/ -- BryceTech CEO Carissa Bryce Christensen has been selected as a GovCon Executive of the Year (up to $75 Million) finalist in the wake of record...

Committee members somewhat reluctantly voted in support of new bivalent versions of COVID vaccines despite a lack of clinical trial data, citing the example of annual flu-shot revisions.

Pending final CDC approval, Americans will soon have the option of getting Novavax’s two-dose, non-mRNA vaccine.

Pending authorization by the FDA, the federal government has secured 3.2 million cases of Novavax’s COVID-19 vaccine.

The Department of Health and Human Services said the U.S. will order more than 3 million doses of Novavax, Inc. COVID-19 vaccine upon emergency authorization.

The U.S. Department of Health and Human Services, in collaboration with the Department of Defense, announced it has secured 3.2 million doses of Novavax's COVID-19 vaccine. The protein-based, adjuvanted vaccine will be made available for free to states, jurisdictions, federal pharmacy partners and federally qualified health centers if it receives U.S. Food and Drug

The Biden administration said Monday it secured 3.2 million doses of the COVID-19 vaccine from Novavax ahead of authorization from the Food and Drug Administration.

The House Ways and Means Committee issued the following testimony by Health and Human Services Secretary Xavier Becerra involving a hearing on April 28, 2022, on the fiscal 2023 budget request:. Thank you for the opportunity to discuss the President's Fiscal Year 2023 Budget for the Department of Health and Human Services. We are proud to be Congress' partner in...

The House Education and Labor Committee issued the following statement by Health and Human Services Secretary Xavier Becerra involving a hybrid hearing on April 6, 2022, entitled "Examining the Policies and Priorities of the U.S. Department of Health and Human Services":. Thank you for the opportunity to discuss the President's Fiscal Year 2023 Budget for the...

This report describes COVID-19 vaccine provider access and vaccination coverage among U.S. children aged 5–11 years.